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Candida species are common human fungal pathogens causing a wide range of clinical 19 
diseases, ranging from superficial infections to life-threatening systemic disease.  Superficial 20 
infections include vaginal candidiasis which affects over 75% of women during their lifetime 21 
with 5% of women suffering debilitating recurrent infections. 1, 2  Life-threatening systemic 22 
Candida disease is the fourth most common nosocomial blood stream infection, affecting 23 
those undergoing chemotherapy, recovering from surgical procedures or major burns, 24 
transplant recipients and AIDs patients.  The crude mortality rate associated with these 25 
infections is high, ranging from 46-75%, and current estimates suggest at least 400,000 life-26 
threatening infections occur annually. 1, 3-6  Candida albicans is the predominant cause of 27 
invasive candidiasis, although in the last three decades there has been a rise in the 28 
incidence of non-albicans Candida species with Candida glabrata, Candida parapsilosis and 29 
Candida tropicalis being the other main agents causing disease.  Of these, C. glabrata is the 30 
second most common cause of invasive candidiasis in the USA and Central and Northern 31 
Europe, and it has been associated with higher hospital costs. 5, 7-9  The basis of this 32 
increasing incidence of C. glabrata is not fully understood, however, it could be partially 33 
attributed to the higher innate tolerance C. glabrata displays to azole antifungals alongside 34 
its greater potential to develop drug resistance coincident with therapy. 10, 11 35 
Murine models of infection are typically viewed as the gold standard for fungal virulence 36 
studies.  However, although these models allow the host-pathogen interaction to be studied 37 
in vivo they do come with caveats associated with cost, legislation, and careful ethical 38 
considerations.  Furthermore, with the development of large scale mutant libraries 39 
alternative, more ethically acceptable, models are required to identify interesting virulence 40 
targets whilst limiting the use of mice. 12, 13  Given the caveats associated with murine 41 
models of infection mini-host models, mainly invertebrates, have been explored as 42 
alternative models for fungal infection.  These models include amoeba (Dictyostellium 43 
discoideum), nematodes (Caenorhabditis elegans), fruit fly (Drosophila melanogaster) and 44 
the greater wax moth larvae (Galleria mellonella). 14-16  G. mellonella, a lepidopteran, was 45 
first described as a mini-host for Candida species by Kavanagh and co-workers 17, 18, and 46 
has received particular attention as an alternative host as it displays some important 47 
advantages.  The G. mellonella larvae can be incubated at 37 ºC, allowing virulence to be 48 
studied at human body temperature, and an exact inoculum of the pathogen can be 49 
delivered by injection.  Furthermore, the assays are inexpensive and simple to perform, 50 
allowing large numbers of larvae to be infected and thus increasing the statistical power of 51 
the assay.  Finally some aspects of the G. mellonella immune response show similarities 52 
with the innate immune response of mammals. 14, 15, 19  Given these advantages the model 53 
has now been developed for a wide range of fungal pathogens, including a number of 54 
Candida species. 17, 18, 20-22 55 
To study C. glabrata infection in mice immunosuppression is usually required, and fungal 56 
burdens and persistence are normally employed as a parameter for virulence due to the 57 
absence of mortality. 23  This, along with the recent development of large scale mutant 58 
libraries, makes alternative models for studying C. glabrata virulence an attractive 59 
proposition.  Initial reports on establishing the G. mellonella model for testing the virulence of 60 
Candida species only reported a low level of killing of larvae by C. glabrata. 18, 24, 25  61 
However, we and others 26, 27 have now shown that a faster rate of killing by C. glabrata is 62 
seen when using a higher pathogen concentration.  In this work we provide the first detailed 63 
report on the ability of C. glabrata to grow and cause lethal infections in G. mellonella in a 64 
dose dependent manner.  Furthermore, we have shown that this model can be used to 65 
assess the relative virulence of C. glabrata clinical isolates, and that the analysis of mutant 66 
strains demonstrates an overlap with results published using murine infection models.  67 
Finally, we have shown that antifungal efficacy in the G. mellonella model correlates with the 68 
in vitro susceptibility profile of C. glabrata.  Therefore, the G. mellonella model can be used 69 
to study both C. glabrata virulence and antifungal efficacy. 70 
In order to evaluate G. mellonella as a host model for C. glabrata infection we first infected 71 
larvae with the commonly used wild type reference strain ATCC2001 28 at a range of 72 
different inoculum levels (7.5 x 105, 1 x 106, 2.5 x 106, 5 x 106 and 7.5 x 106 cells/larva).  For 73 
this, groups of twenty healthy larvae (0.25-0.35g) were inoculated with 10 µl of cell 74 
suspension through injection into the haemocoel with a Hamilton syringe through the last left 75 
pro-leg.  Following infection larvae were incubated in the dark at 37 ºC and survival, based 76 
on response to physical stimulation, was monitored daily for seven days.  Larvae inoculated 77 
with PBS were used as uninfected controls and resulted in no deaths (data not shown), and 78 
all assays were performed at least three times independently.  The results from this clearly 79 
demonstrated that C. glabrata can kill the larvae in a dose dependent fashion (Fig. 1A).  For 80 
example, infection with 2.5 x 106 cells/larva gave a mean survival time of 3.45 ± 0.28 days 81 
compared to 1.63 ± 0.13 days with an infective dose of 7.5 x 106 cells/larva (P<0.0001).  The 82 
infective dose required for C. glabrata to kill G. mellonella larvae was however approximately 83 
ten fold higher than the dose of C. albicans required to cause death, where an infective dose 84 
of 2 x 105 cells/larva C. albicans NGY152 29 cells resulted in a mean survival time of 2.95 ± 85 
0.21 days (data not shown) similar to previous reports. 17, 18, 22  Similar findings have been 86 
seen with other Candida species, 20-22 and for C. glabrata is perhaps in keeping with its 87 
differing virulence properties favouring stealth and evasion over aggressive invasion. 23, 30  88 
Given the high dose of C. glabrata required to cause G. mellonella killing we also evaluated 89 
the survival of larvae inoculated with heat-killed yeast cells (incubated at 75 ºC for 20 min 90 
before use), to ensure that killing was not due to other factors such as toxic shock.  No larval 91 
death was seen following infection with heat-killed cells at 5 x 106 cells/larva (data not 92 
shown); therefore the killing of larvae in this model is dependent on viable C. glabrata cells. 93 
Temperature has been seen to impact on the outcome of G. mellonella infection for some 94 
fungal species, with both C. albicans and C. tropicalis displaying faster killing following 95 
incubation at 37 ºC rather than 30 ºC whereas killing rates following C. krusei infection were 96 
not affected by temperature. 21, 22, 31  To determine if temperature also impacts on the 97 
virulence of C. glabrata we compared the virulence of C. glabrata ATCC2001 at 30 and 37 98 
ºC.  At the intermediate infective doses of both 1 x 106 and 2.5 x 106 cells/larva C. glabrata 99 
virulence was significantly decreased at 30 ºC compared to 37 ºC (Fig. 1B, P<0.005).  For 100 
example, with the 2.5 x 106 cells/larva dose the mean survival time at 30 ºC was 4.65 ± 0.33 101 
days compared to 3.45 ± 0.28 days at 37 ºC.  However, no significant impact of temperature 102 
was seen when higher infective doses were employed, suggesting this limitation can be 103 
overcome.  The increased mortality seen at higher temperatures with intermediate infective 104 
doses may be the result of the impact of temperature on both the growth and virulence 105 
properties of the pathogen, plus the effect of temperature on the immune response of the 106 
larvae. 32 107 
Following infection with C. glabrata larvae quickly developed a brown-black colouration, 108 
indicative of the accumulation of melanin as part of the insect innate immune response.  To 109 
quantify this hemolymph was collected from infected larvae, at 2 and 6 hours post infection, 110 
following established methods. 33  The extent of melanisation was then determined through 111 
measuring the hemolymph optical density at 405 nm, which correlates with its visual 112 
appearance and has been used previously to quantify laccase activity.  22  Through this the 113 
extent of melanisation was seen to be dependent on both the infective dose of C. glabrata 114 
and time post infection (Fig 1C).  In addition to the activation of melanisation, previous work 115 
has demonstrated that the density of free hemocytes in the hemolymph is decreased 116 
following infection with C. albicans and other microbes. 21, 22, 24  This decrease was seen to 117 
correlate with susceptibility to infection, and is thought to be the result of nodulation or 118 
clumping of hemocytes, pathogens and melanised debris at the infection site. 19  Following 119 
infection with C. glabrata, at 2.5 x 106 cells/larva, we also saw a significant decrease in total 120 
hemocyte cell density, with levels falling from 8.5 x 106 ± 2.0 x 106 cells/ml for PBS 121 
inoculated control larvae to 4.6 x 106 ± 1.2 x 106 (54%; p<0.01) and 2.7 x 106 ± 9.7 x 105 122 
(33%; p<0.005) at 2 and 6 hours post infection respectively.  Overall therefore, with the 123 
activation of melanisation and the drop in free hemocyte density, it is clear that the larvae 124 
mount a defence response following C. glabrata infection. 125 
To follow the progress of infection we also determined the fungal burdens in G. mellonella, at 126 
0, 6, 24, 48 and 72 h post infection, following inoculation with 2.5x106 cells/larva C. glabrata 127 
ATCC2001.  For this nine larvae were taken at each time point, briefly washed in 70 % 128 
ethanol followed by sterile water, and then placed into 15 ml screw-cap tubes with four 3 mm 129 
stainless steel balls and 1 ml PBS.  The tissue was then homogenised through three rounds 130 
of shaking for 20 s at 4 m/s in a Fastprep-24 (MP Biomedicals).  The resulting homogenate 131 
was then suspended in 14 ml PBS and serial dilutions prepared and inoculated onto YEPD-132 
chloramphenicol (100 µg/ml) plates.  Immediately following infection the detectable fungal 133 
burden was 5.8 x105 ± 3.4 x 105 CFU/larvae, and initially remained fairly constant only 134 
reaching 8.5 x105 ± 6 x105 CFU/larvae at 6 h post infection.  However, by 24 h, when larvae 135 
began to succumb to infection, fungal burdens had risen ~20 fold to 1.2 x107 ± 9.4 x106 136 
CFU/larvae and continued to rise at 48 and 72 h post infection (Fig. 1D), demonstrating 137 
growth of the C. glabrata in the host. 138 
In addition to testing the ability of C. glabrata ATCC2001 to cause lethal infection in G. 139 
mellonella we also screened a further five clinical isolates (BG2, Cg1184, Cg85/038, 140 
Cg11088A and NCPF3605) 34-37, including the other commonly used isolate BG2, at three 141 
infective doses (1.25 x 106, 2.5 x 106 and 5 x 106 cells/larva; Fig. 2).  All strains 142 
demonstrated a dose dependent response, and four of these strains (BG2, Cg1184, 143 
Cg85/038 and Cg11088A) demonstrated a very similar level of virulence to ATCC2001.  144 
Indeed when comparing the different infective doses the only significant difference was the 145 
slight increase in virulence seen with strain Cg1184 at the 5 x 106 cells/larva dose compared 146 
to BG2 (P<0.005) and Cg11088A (P<0.05).  Therefore the majority of C. glabrata isolates 147 
tested show broadly similar levels of virulence in this model.  The only key exception was the 148 
NCPF3605 strain which, at all infective doses tested, was clearly highly attenuated in 149 
virulence compared to all the other isolates (P<0.0001) only causing 22.5% ± 9.6% killing of 150 
larvae by 7 days at the highest dose tested.  A recent comparison of the growth of this strain 151 
and ATCC2001, at varying glucose concentrations, demonstrated distinct differences, with 152 
NCPF3605 displaying a faster growth rate but at the cost of entering stationary phase at a 153 
lower cell density. 38  General fitness defects may therefore impact on the virulence of C. 154 
glabrata in this model and, importantly, the G. mellonella model can be used to detect 155 
differences in the virulence potential of C. glabrata strains. 156 
Auxotrophic markers are commonly used for selection during the genetic modification of 157 
Candida species.  However, in C. albicans it is well recognised that ura3 auxotrophy causes 158 
virulence to be highly attenuated in the mouse model of infection, and that the level of 159 
expression of URA3 can also impact on virulence. 29, 39  In this work we have demonstrated 160 
that ura3 auxotrophy has a similar impact on the virulence of C. glabrata in the G. mellonella 161 
infection model.  G. mellonella infected with 2. 5 x106 cells/larva of wild type C. glabrata 162 
(ATCC2001) demonstrated a mean survival time of 2.90 ± 0.19 days compared to 6.39 ± 163 
0.13 days (p<0.0001) for those infected with a ura3 auxotroph (strain 2001U 40).  Given the 164 
known issues with ura3 auxotrophy in C. albicans, most work in C. glabrata uses other 165 
auxotrophic markers that have been shown not to impact on virulence in mice. 23, 41  We 166 
therefore also screened his3, leu2 and trp1 single mutants (strains 2001H, 2001L and 2001T 167 
respectively) and a his3, leu2, trp1 triple mutant (strain 2001HTL). 41  Similar to the situation 168 
in a mouse model, loss of HIS3 or LEU2 did not impact on microbial virulence within the G. 169 
mellonella model (data not shown).  However, in our model we did detect a subtle, but 170 
significant, attenuation of virulence in the trp1 single (mean survival time 3.67 ± 0.20 days, 171 
p=0.0173) and his3, leu2, trp1 triple null mutant (mean survival time 3.87 ± 0.20 days, 172 
p=0.0020) compared to the wild type strain ATCC2001 (mean survival time of 2.90 ± 0.19 173 
days).  It is tempting to attribute the lower virulence of the triple mutant to its loss of trp1; 174 
however, as we did not test this empirically we cannot rule out the possibility that the 175 
combined auxotrophies also impact on fitness and ultimately virulence.  Overall, we would 176 
therefore suggest that when using this model it is important to ensure appropriate control 177 
strains, displaying the same auxotrophies, are employed. 178 
In order to assess the utility of this model to screen defined mutants for virulence defects we 179 
also carried out virulence assays with fourteen deletion mutants, including eight whose 180 
phenotype in a mouse model of infection has previously been reported.  These included 181 
twelve mutants associated with C. glabrata stress responses (ste50, ste20, hog1, skn7, 182 
yap1, cta1, rim101, yps1, msn2, msn4, cst6 and slt2) 41-43 plus two glycosylation 183 
mutants (mnn2 and anp1) 44 that have previously been shown to be hypervirulent in mice.  184 
In order to increase the statistical power of the assay we used fifty larvae per replicate, and 185 
selected one infective dose (2.5 x 106 cells/larva) which would allow either an increase or 186 
decrease in virulence potential to be observed.  Virulence was then compared to the relevant 187 
wild type strain (2001HTL, 2001H or HT6 41, 43), selected based on the genetic background of 188 
the mutant.  Through this analysis we identified five mutants that demonstrated a mild but 189 
significant attenuation in virulence, including ste50, ste20, hog1 in the Hog pathway, 190 
slt2 in the cell wall integrity pathway and skn7 involved in oxidative stress resistance 191 
(Table 1).  The level of attenuation in these mutants was generally subtle, but shown to be 192 
significant through the benefit of being able to infect a large number of larvae in order to 193 
increase the statistical power of the assay.  Of these mutants four, ste20, hog1, slt2 and 194 
skn7, have previously been tested in a mouse model of systemic infection where they also 195 
displayed a mild (ste20, slt2 and skn7) to moderate (hog1) attenuation of virulence. 45-196 
48  For STE50 this is the first report of its importance in virulence, and the phenotype 197 
displayed by the ste50 mutant is in keeping with the overall importance of the Hog1 198 
pathway.  Furthermore, the large scale analysis of C. glabrata mutants in the Drosophila 199 
infection model 13 also identified both the Hog1 and cell wall integrity pathways as playing a 200 
key role in virulence, therefore the importance of these pathways has been consistently 201 
demonstrated in three different infection models.  The remaining mutants (yap1, cta1, 202 
rim101, yps1, msn2, msn4 and cst6; Table 1) displayed no significant defect in 203 
virulence, and of these two (yap1 and cta1) have also previously been reported to display 204 
no virulence defect in mice. 49, 50  In addition to the stress response mutants we also 205 
screened two glycosylation mutants (mnn2 and anp1) 44 that have previously been shown 206 
to demonstrate increased virulence in a mouse model of infection.  Intriguingly, these 207 
deletion mutants also displayed increased virulence in the G. mellonella model whilst their 208 
complemented strains demonstrated wild type virulence (Table 1).  The molecular basis of 209 
this hypervirulence is currently not clear, but the mutants are known to be hyperadherent 210 
and potentially elicit a septic-shock like response. 44  This may therefore suggest that either 211 
similar components are involved in the recognition of the pathogen by G. mellonella or 212 
common adhesins play a role in both models.  Overall, of the fourteen mutants tested in this 213 
study eight have previously been screened in mice and we have shown all to display 214 
comparable phenotypes in the G. mellonella model, plus confirm the importance of the Hog1 215 
and cell wall integrity pathways in virulence.  This correlation is very encouraging and 216 
suggests that this model has the potential to be used to screen for novel virulence factors in 217 
C. glabrata 218 
In order to facilitate the future use of this model for comparing mutant strains, potentially 219 
through large scale screening efforts, we also calculated a larval virulence index (LVI) as a 220 
measure of virulence for the set of fourteen mutants tested.  For this we followed the 221 
methodology established for use with the Drosophila infection model. 13, 41  Survival curves 222 
were initially fitted to a Weibull distribution, then the time of 50% larval survival (LT50) 223 
determined and from this the LVI presented as the log2 ratio of mutant and corresponding 224 
wild type control (Table 1).  The LT50 values determined for the different strains were, as 225 
expected, in very strong agreement with their mean survival times (Spearman’s rho=0.99, 226 
P<0.00001).  Furthermore, applying the cut-offs established by Brunke et al. 13 for increased 227 
or decreased virulence (virulence index ±0.5), six of the seven mutants we identified as 228 
displaying altered virulence through the traditional log rank tests were also highlighted by 229 
this approach.  The mutant not highlighted, ste20, was on the verge of detection with a LVI 230 
of -0.46 and was also the least attenuated in virulence through the traditional log rank test.  231 
Overall, therefore, this modelling approach gives a strong quantitative measure of virulence, 232 
and may facilitate the future use of this model in the large scale screening of available C. 233 
glabrata deletion libraries. 41 234 
Finally, we also tested the efficacy of fluconazole, amphotericin B, and caspofungin against 235 
C. glabrata in the G. mellonella model and compared this to C. albicans.  C. glabrata is well 236 
recognised for displaying a higher innate tolerance to azole antifungals than C. albicans. 10, 11  237 
Consistent with this, although C. albicans NGY152 was highly sensitive to fluconazole in 238 
vitro the C. glabrata strain ATCC2001 displayed a high MIC of 32 µg/ml, whereas for 239 
caspofungin and amphotericin B both were acutely sensitive.  We next tested the efficacy of 240 
these antifungals in the G. mellonella model at clinically relevant doses that did not cause 241 
toxicity in the model (data not shown).  For this, larvae were infected with 1 x 105 cells/larva 242 
C. albicans NGY152 or 1.25 x 106 cells/larva C. glabrata ATCC2001 and antifungals 243 
administered 30 min post infection through a second 10 µl injection into the pro-leg adjacent 244 
to the site of initial infection.  Untreated controls received a second injection of PBS.  For G. 245 
mellonella infected with C. albicans, treatment with fluconazole at all concentrations tested 246 
(3, 6, and 12 mg/kg) promoted survival (Fig 3A; P<0.0001).  In contrast treatment with the 247 
same levels of fluconazole provided no protection against C. glabrata infection (Fig. 3B).  248 
Amphotericin B at both 2 and 4 mg/kg also protected larvae against infection by C. albicans 249 
(Fig. 3C; P<0.0001), whereas only the highest concentration (4 mg/kg) provided significant 250 
protection against C. glabrata (Fig. 3D; P<0.0001).  Finally, caspofungin also protected G. 251 
mellonella against C. albicans infection at all concentrations tested (Fig. 3E, 1 mg/kg 252 
P<0.005; 2 and 4 mg/kg P<0.0001), whereas again only the higher doses of 2 and 4 mg/kg 253 
provided significant protection against C. glabrata infection (Fig. 3F, P<0.0001).  We 254 
therefore saw a clear correlation between in vitro susceptibility and in vivo efficacy in this 255 
model for C. glabrata, consistent with previous studies demonstrating the potential of the G. 256 
mellonella model to be used in testing the toxicity and efficacy of antifungal agents for a 257 
range of fungal pathogens. 21, 22, 31, 51, 52  Interestingly, although amphotericin B and 258 
caspofungin did provide protection against C. glabrata, in both cases a higher dose of 259 
antifungal was required to achieve efficacy than for treatment of C. albicans.  A similar profile 260 
was seen following infection with C. krusei and this was associated with the strain tested, 261 
although being susceptible, demonstrating reduced susceptibility compared to the C. 262 
albicans control strain. 22  In this work however, the C. glabrata and C. albicans strains 263 
employed demonstrated very similar susceptibility profiles towards amphotericin B and 264 
caspofungin.  The basis of this subtle but consistent in vivo susceptibility shift is therefore not 265 
clear.  It could simply be due to the requirement of a tenfold higher infective dose for C. 266 
glabrata compared to C. albicans, which may result in the need for a higher drug 267 
concentration, or alternatively it could be suggestive of C. glabrata displaying a higher in vivo 268 
tolerance towards antifungals. 269 
Infection models utilising G. mellonella are generally gaining acceptance and have now been 270 
established for a range of fungal pathogens.  As previously discussed these models present 271 
some advantages through being more ethically acceptable, inexpensive allowing the use of 272 
more test subjects to increase the statistical power of the assay, alongside the easy 273 
manipulation of larvae and ability to assay at 37 ºC.  There are however some 274 
disadvantages such as no complete genome sequence and the lack of genetic tractability in 275 
G. mellonella, plus an inherent level of variability in the quality of larvae from suppliers.  276 
Finally, as with any infection model, it is unlikely that all virulence attributes involved in 277 
mammalian infection will demonstrate similar importance in the G. mellonella system.  278 
Overall however we would conclude that G. mellonella is an attractive and simple model for 279 
following C. glabrata infection.  High doses are initially required to cause an infection, but 280 
once established a simple to follow lethal infection coupled with growth of the pathogen and 281 
a detectable host response is seen.  Furthermore, through the mutants tested, we saw a 282 
good level of correlation with murine models suggesting that this system has the potential to 283 
be used to screen for novel virulence factors in this important pathogen.  Finally, as has 284 
been seen with other fungal pathogens, this system can clearly be employed for the in vivo 285 
evaluation of antifungal agents. 286 
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  450 
Table 1. Virulence of C. glabrata mutants in the G. mellonella model.   451 
Strain Mean Survival Time 
(days) 





Wild type (2001HTL) 41 2.41 ± 0.12 - 1.37 - 
hog1 41 3.30 ± 0.41 <0.005 2.31 -0.52 
skn7 41 3.87 ± 0.25 <0.0001 3.30 -0.88 
rim101 41 2.27 ± 0.09 N.S. 1.34 0.02 
yps1 41 2.87 ± 0.11 N.S. 1.84 -0.30 
Wild type (2001HTL) 41 2.32 ± 0.12 - 1.29 - 
ste50 41 3.99 ± 0.10 <0.0001 3.22 -0.92 
slt2 41 3.26 ± 0.23 <0.0005 2.26 -0.56 
ste20 41 3.09 ± 0.19 <0.01 2.04 -0.46 
cta1 41 2.41 ± 0.16 N.S. 1.45 -0.12 
Wild type (HT6) 43 2.44 ± 0.19 - 1.42 - 
yap1 42 2.57 ± 0.42 N.S. 1.48 -0.04 
Wild type (2001H) 41 3.32 ± 0.37 - 2.30 - 
msn4 41 3.40 ± 0.25 N.S. 2.41 -0.05 
cst6 41 3.01 ± 0.15 N.S. 2.06 0.11 
msn2 41 2.93 ± 0.20 N.S. 1.92 0.18 
Wild type (HT6) 43 3.17 ± 0.28 - 2.20 - 
mnn2 44 2.11 ± 0.16 <0.0001 1.22 0.59 
mnn2+MNN2 44 3.29 ± 0.48 N.S. 2.30 -0.05 
Wild type (HT6) 43 2.79 ± 0.09 - 1.71 - 
anp1 44 1.54 ± 0.16 <0.0001 0.73 0.85 
anp1+ANP1 44 2.64 ± 0.13 N.S. 1.57 0.09 
(L.V.I. Larval virulence index, N.S. Not significant) 452 
  453 
Figure 1.  Virulence of C. glabrata in G. mellonella.  (A and B) Survival curves of G. 454 
mellonella infected with C. glabrata ATCC2001 at 7.5 x 105 (squares), 1 x 106 (triangles), 2.5 455 
x 106 (upside-down triangles), 5 x106 (diamonds) and 7.5 x 106 (circles) cells/larva at 37 ºC 456 
(A) and 30 ºC (B).  At 37 ºC (A) all infective doses displayed significant differences (p<0.05), 457 
whereas at 30 ºC (B) all doses displayed significant differences (p<0.05) except between the 458 
two lowest infective doses (7.5 x 105 and 1 x 106 cells/larva). (C) Larvae were infected with 459 
C. glabrata ATCC2001 at 1 x 106, 2.5 x 106, and 5 x106 cells/larva and at 2 and 6 hours post 460 
infection hemolymph was collected from larvae and OD405 determined to quantify melanin 461 
production.  Larvae inoculated with PBS were used as a control, and asterisks denote a 462 
statistically significant difference to the PBS control (p<0.05). (D) G. mellonella were infected 463 
with C. glabrata ATCC2001 at 2.5 x 106 cells/larva and fungal burdens determined at the 464 
time points indicated.  Scatterplots depict combined results from three independent 465 
replicates using nine larvae for each time point. 466 
Figure 2.  Virulence of C. glabrata clinical isolates in G. mellonella.  Survival curves of 467 
G. mellonella infected with C. glabrata ATCC2001 (open squares), NCPF3605 (closed 468 
squares), BG2 (triangles), Cg1184 (upside-down triangles), Cg85/038 (diamonds), and 469 
Cg11088A (circles) at 1 x 106 (A), 2.5 x 106 (B), and 5 x106 (C) cells/larva.  At all doses 470 
strain NCPF3605 was highly attenuated compared to all other strains (p<0.0001); plus at the 471 
highest dose (C) a slight but significant increase in virulence was seen for Cg1184 compared 472 
to BG2 (p<0.005) and Cg11088A (p<0.05),  473 
Figure 3.  Antifungal efficacy against C. albicans and C. glabrata in the G. mellonella 474 
model.  Survival curves of G. mellonella infected with 1 x 105 cells/larva C. albicans 475 
NGY152 (A, C and E) or 1.25 x 106 cells/larva C. glabrata ATCC2001 (B, D and F).  (A and 476 
B) Fluconazole treatment at 0 (squares), 3 (triangle), 6 (diamonds) or 12 mg/kg (circles).  (C, 477 
D, E and F) Amphotericin B or Caspofungin treatment at 0 (squares), 1 (triangle), 2 478 
(diamonds) or 4 mg/kg (circles). 479 



